GUSTO II trial.

P. Aylward

doi:10.1111/j.1445-5994.1993.tb04760.x

GUSTO II trial.

P. Aylward

College of Medicine and Public Health

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

The GUSTO II trial will investigate the role of antithrombin therapy in acute coronary syndromes, comparing standard doses of heparin with the specific antithrombin agent recombinant hirudin. The two drugs will be compared as primary therapy in patients with unstable angina or patients with myocardial infarction (MI) unsuitable for thrombolysis, and as post thrombolysis treatment in patients who fulfil standard criteria for thrombolysis therapy. A total of 12,000 patients will be studied in a global, multifactorial trial.

Original language	English
Pages (from-to)	766-768
Number of pages	3
Journal	Australian and New Zealand Journal of Medicine
Volume	23
Issue number	6
DOIs	https://doi.org/10.1111/j.1445-5994.1993.tb04760.x
Publication status	Published - Dec 1993

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1445-5994.1993.tb04760.x

Cite this

@article{471254fc7049485eb0bd1f1ac05d0065,

title = "GUSTO II trial.",

abstract = "The GUSTO II trial will investigate the role of antithrombin therapy in acute coronary syndromes, comparing standard doses of heparin with the specific antithrombin agent recombinant hirudin. The two drugs will be compared as primary therapy in patients with unstable angina or patients with myocardial infarction (MI) unsuitable for thrombolysis, and as post thrombolysis treatment in patients who fulfil standard criteria for thrombolysis therapy. A total of 12,000 patients will be studied in a global, multifactorial trial.",

author = "P. Aylward",

year = "1993",

month = dec,

doi = "10.1111/j.1445-5994.1993.tb04760.x",

language = "English",

volume = "23",

pages = "766--768",

journal = "Australian and New Zealand Journal of Medicine",

issn = "0004-8291",

publisher = "John Wiley & Sons, Inc",

number = "6",

}

TY - JOUR

T1 - GUSTO II trial.

AU - Aylward, P.

PY - 1993/12

Y1 - 1993/12

N2 - The GUSTO II trial will investigate the role of antithrombin therapy in acute coronary syndromes, comparing standard doses of heparin with the specific antithrombin agent recombinant hirudin. The two drugs will be compared as primary therapy in patients with unstable angina or patients with myocardial infarction (MI) unsuitable for thrombolysis, and as post thrombolysis treatment in patients who fulfil standard criteria for thrombolysis therapy. A total of 12,000 patients will be studied in a global, multifactorial trial.

AB - The GUSTO II trial will investigate the role of antithrombin therapy in acute coronary syndromes, comparing standard doses of heparin with the specific antithrombin agent recombinant hirudin. The two drugs will be compared as primary therapy in patients with unstable angina or patients with myocardial infarction (MI) unsuitable for thrombolysis, and as post thrombolysis treatment in patients who fulfil standard criteria for thrombolysis therapy. A total of 12,000 patients will be studied in a global, multifactorial trial.

UR - http://www.scopus.com/inward/record.url?scp=0027865593&partnerID=8YFLogxK

U2 - 10.1111/j.1445-5994.1993.tb04760.x

DO - 10.1111/j.1445-5994.1993.tb04760.x

M3 - Article

C2 - 8141723

AN - SCOPUS:0027865593

SN - 0004-8291

VL - 23

SP - 766

EP - 768

JO - Australian and New Zealand Journal of Medicine

JF - Australian and New Zealand Journal of Medicine

IS - 6

ER -

GUSTO II trial.

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this